FDA Brief

Warning letters Drugs

FDA warning letter to

Functional Remedies, LLC D/B/A Synchronicity Hemp Oil

High riskIssued Mar 28, 2022Posted Mar 29, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC told a Louisville, Colorado hemp and CBD seller that its website claims the products treat or prevent COVID-19, making them unapproved and misbranded drugs.

What happened

FDA reviewed the company's website on February 16, 2022, and the Federal Trade Commission reviewed it on March 1, 2022. Both agencies found blog posts, including one from November 24, 2020, saying hemp oil might reduce the dangerous inflammation seen in COVID-19 patients and that CBD could lower the receptors the virus uses to enter cells. FDA said these statements show the products are intended to treat or prevent COVID-19, which makes them unapproved new drugs.

What FDA found

  1. The hemp and CBD products are being sold as drugs to treat or prevent COVID-19 without FDA approval.

    Section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a)
  2. The products' labeling is misleading because it presents them as safe and effective for a use FDA has not approved.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Shipping these products across state lines is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertises that its products prevent, treat or cure a disease without competent and reliable scientific evidence to back the claims.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. Deceptive claims about treating, curing, preventing or mitigating COVID-19 can bring a civil penalty of up to $46,517 per violation and may require consumer refunds.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260; Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b)

What FDA wants

Within 48 hours, email FDA's COVID-19 Task Force at COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. The company must also email the FTC within 48 hours certifying that it has stopped making the unsubstantiated claims.

Who should pay attention

  • CBD and hemp brands that publish health or disease claims on their websites
  • marketing and e-commerce staff at supplement companies
  • retailers and distributors carrying CBD products with disease claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk